Magazine article from our research archive:

Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib

Dear Sir,

The concept of targeted therapy is emerging as an innovative, high potential new trend in cancer therapy. These drugs are not supposed to affect the normal cells and act selectively on cancer cells there by minimizing the systemic side-effects. However the results are not as expected. One of such novel drugs (first of its kind to be approved by FDA) is Imatinib, a Bcr-Abl tyrosine kinase inhibitor. It has been used in patients of chronic myeloid leukemia and Gastro Intestinal Stromal Tumor (GIST) and has been under evaluation for many more indications. It is usually well tolerated, with relatively minor toxicities like fluid retention and skin changes. However, with the time, ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!